Free Trial
→ Musk’s Project Colossus could mint millionaires (From Brownstone Research) (Ad) Buy VIR Stock  Free VIR Stock Alerts

Vir Biotechnology (VIR) Financials

Vir Biotechnology logo
$5.19 +0.43 (+9.03%)
Closing price 04:00 PM Eastern
Extended Trading
$5.10 -0.09 (-1.73%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Vir Biotechnology

Annual Income Statements for Vir Biotechnology

This table shows Vir Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Net Income / (Loss) Attributable to Common Shareholders		 -522 -615 516 529 -299 -175 -116 -70
Consolidated Net Income / (Loss)		 -522 -615 516 529 -299 -175 -116 -70
Net Income / (Loss) Continuing Operations		 -522 -615 516 529 -299 -175 -116 -70
Total Pre-Tax Income 		-523 -628 754 550 -299 -175 -116 -81
Total Operating Income		 -587 -684 833 421 -297 -178 -119 -81
Total Gross Profit		 73 83 1,469 1,030 76 8.09 11 2.71
Total Revenue		 74 86 1,616 1,095 76 8.09 11 2.71
Operating Revenue		 74 86 1,616 1,095 76 8.09 11 2.71
Total Cost of Revenue		 0.85 2.77 146 66 0.00 0.00 0.00 0.00
Operating Cost of Revenue		 0.85 2.77 146 66 0.00 0.00 - -
Total Operating Expenses		 661 768 636 609 373 186 129 84
Selling, General & Admin Expense		 119 174 162 161 71 38 29 22
Research & Development Expense		 506 580 475 448 302 148 100 63
Restructuring Charge		 35 14 0.00 - - - - -
Total Other Income / (Expense), net		 64 56 -79 129 -1.63 3.45 2.33 0.72
Interest & Investment Income		 72 87 28 0.44 - - - 0.64
Other Income / (Expense), net		 -7.75 -31 -107 129 -4.47 -5.06 -0.21 0.08
Income Tax Expense		 -1.15 -13 238 21 0.05 0.15 -0.48 -11
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.00 -0.06 0.00 0.00 - - - -
Basic Earnings per Share		 ($3.83) ($4.59) $3.89 $4.07 ($2.51) ($5.76) ($15.12) ($32.45)
Weighted Average Basic Shares Outstanding		 136.25M 134.13M 132.61M 129.88M 119.16M 30.35M 7.67M 2.15M
Diluted Earnings per Share		 ($3.83) ($4.59) $3.83 $3.96 ($2.51) ($5.76) ($15.12) ($32.45)
Weighted Average Diluted Shares Outstanding		 136.25M 134.13M 134.81M 133.44M 119.16M 30.35M 7.67M 2.15M
Weighted Average Basic & Diluted Shares Outstanding		 137.14M 135.03M 133.53M 132.30M 119.16M 30.35M 7.67M 2.15M

Quarterly Income Statements for Vir Biotechnology

This table shows Vir Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -121 -105 -214 -138 -65 -116 -163 -195 -141 -102 175
Consolidated Net Income / (Loss)		 -121 -105 -214 -138 -65 -116 -163 -195 -141 -102 175
Net Income / (Loss) Continuing Operations		 -121 -105 -214 -138 -65 -116 -163 -195 -141 -102 175
Total Pre-Tax Income 		-121 -105 -214 -140 -65 -121 -167 -198 -143 -152 218
Total Operating Income		 -140 -117 -231 -159 -80 -139 -187 -215 -143 -151 195
Total Gross Profit		 3.03 12 2.33 3.02 56 16 2.60 3.78 61 43 352
Total Revenue		 3.03 12 2.38 3.08 56 17 2.64 3.80 63 49 375
Operating Revenue		 3.03 12 2.38 3.08 56 17 2.64 3.80 63 49 375
Total Cost of Revenue		 0.00 0.68 0.05 0.05 0.06 0.80 0.04 0.02 1.91 6.00 22
Operating Cost of Revenue		 0.00 0.68 0.05 0.05 0.06 0.80 0.04 0.02 1.91 6.00 22
Total Operating Expenses		 143 129 234 162 136 155 189 219 204 194 157
Selling, General & Admin Expense		 24 27 26 30 36 41 41 46 47 39 43
Research & Development Expense		 119 106 195 105 100 109 145 168 158 155 114
Restructuring Charge		 -0.01 - 13 26 - - 3.37 5.37 - - -
Total Other Income / (Expense), net		 19 12 18 19 15 18 20 18 0.18 -1.14 23
Interest & Investment Income		 12 - 18 - 21 - 22 - - - 9.33
Other Income / (Expense), net		 6.31 -1.68 0.24 -0.11 -6.20 -2.48 -1.83 -5.45 -21 -17 13
Income Tax Expense		 0.02 -0.09 0.18 -1.51 0.28 -4.78 -3.21 -2.85 -2.23 -50 42
Basic Earnings per Share		 ($0.88) ($0.77) ($1.56) ($1.02) ($0.48) ($0.86) ($1.22) ($1.45) ($1.06) ($0.78) $1.32
Weighted Average Basic Shares Outstanding		 137.47M 136.25M 136.65M 136.23M 135.28M 134.13M 134.29M 134.06M 133.55M 132.61M 132.73M
Diluted Earnings per Share		 ($0.88) ($0.77) ($1.56) ($1.02) ($0.48) ($0.86) ($1.22) ($1.45) ($1.06) ($0.74) $1.30
Weighted Average Diluted Shares Outstanding		 137.47M 136.25M 136.65M 136.23M 135.28M 134.13M 134.29M 134.06M 133.55M 134.81M 134.96M
Weighted Average Basic & Diluted Shares Outstanding		 138.24M 137.14M 137.72M 136.64M 136.06M 135.03M 134.52M 134.25M 133.98M 133.53M 133.12M

Annual Cash Flow Statements for Vir Biotechnology

This table details how cash moves in and out of Vir Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Net Change in Cash & Equivalents		 57 -607 505 -88 329 63 -130 175
Net Cash From Operating Activities		 -446 -779 1,663 -48 -191 -130 -94 -66
Net Cash From Continuing Operating Activities		 -446 -779 1,663 -48 -191 -130 -94 -66
Net Income / (Loss) Continuing Operations		 -522 -615 516 529 -299 -175 -116 -70
Consolidated Net Income / (Loss)		 -522 -615 516 529 -299 -175 -116 -70
Depreciation Expense		 15 19 6.78 5.28 4.40 3.29 1.62 0.26
Amortization Expense		 5.40 -8.71 -8.94 0.29 2.59 1.04 0.81 0.18
Non-Cash Adjustments To Reconcile Net Income		 143 131 500 -61 33 24 7.35 9.10
Changes in Operating Assets and Liabilities, net		 -87 -306 650 -521 68 17 12 -6.06
Net Cash From Investing Activities		 499 165 -1,193 -141 -9.86 -256 -60 -30
Net Cash From Continuing Investing Activities		 499 165 -1,193 -141 -9.86 -256 -60 -30
Purchase of Property, Plant & Equipment		 -7.30 -22 -68 -22 -6.55 -8.94 -9.94 -2.74
Purchase of Investments		 -1,235 -2,016 -1,477 -420 -404 -644 -123 0.00
Sale of Property, Plant & Equipment		 3.37 0.00 0.00 - 0.00 0.00 0.03 0.00
Sale and/or Maturity of Investments		 1,739 2,202 352 301 400 397 73 0.00
Net Cash From Financing Activities		 4.39 7.48 35 100 529 449 25 271
Net Cash From Continuing Financing Activities		 4.39 7.48 35 100 529 449 25 271
Repayment of Debt		 -0.17 -0.29 -0.26 - - 3.27 0.00 0.00
Issuance of Common Equity		 3.76 4.28 32 88 530 126 0.00 0.00
Other Financing Activities, net		 0.79 3.48 3.34 13 -0.44 2.23 11 0.00
Cash Income Taxes Paid		 0.79 2.68 -252 0.00 0.00 - - -

Quarterly Cash Flow Statements for Vir Biotechnology

This table details how cash moves in and out of Vir Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 49 54 -53 137 -81 -211 -215 -156 -25 -116 -543
Net Cash From Operating Activities		 -78 -88 -171 -78 -109 -108 -156 -389 -126 35 118
Net Cash From Continuing Operating Activities		 -78 -88 -171 -78 -109 -108 -156 -389 -126 35 118
Net Income / (Loss) Continuing Operations		 -121 -105 -214 -138 -65 -116 -163 -195 -141 -102 175
Consolidated Net Income / (Loss)		 -121 -105 -214 -138 -65 -116 -163 -195 -141 -102 175
Depreciation Expense		 2.87 2.89 2.90 4.26 4.52 4.48 4.59 4.75 5.64 2.35 1.55
Amortization Expense		 4.09 2.17 0.35 2.64 0.24 1.35 2.31 -3.00 -9.37 -8.03 -2.91
Non-Cash Adjustments To Reconcile Net Income		 9.83 32 21 56 33 35 31 57 7.97 28 -1.06
Changes in Operating Assets and Liabilities, net		 26 -20 18 -2.54 -82 -33 -30 -253 11 114 -55
Net Cash From Investing Activities		 127 141 119 212 28 -105 -59 230 98 -153 -663
Net Cash From Continuing Investing Activities		 127 141 119 212 28 -105 -59 230 98 -153 -663
Purchase of Property, Plant & Equipment		 -1.63 -2.41 -2.36 -0.67 -1.87 -1.54 -3.71 -9.46 -6.87 -13 -19
Purchase of Investments		 -174 -161 -240 -271 -563 -819 -503 -310 -385 -407 -728
Sale of Property, Plant & Equipment		 0.28 2.46 0.01 0.38 0.53 - - - 0.00 -0.02 0.01
Sale and/or Maturity of Investments		 302 301 362 483 593 716 448 550 489 267 85
Net Cash From Financing Activities		 0.60 1.26 0.03 2.94 0.15 1.68 0.28 3.18 2.34 2.01 1.99
Net Cash From Continuing Financing Activities		 0.60 1.26 0.03 2.94 0.15 1.68 0.28 3.18 2.34 2.01 1.99
Other Financing Activities, net		 0.60 0.27 0.03 0.34 0.15 0.29 0.28 0.67 2.24 1.12 1.99

Annual Balance Sheets for Vir Biotechnology

This table presents Vir Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018
Total Assets		 1,399 1,919 2,802 1,954 919 512 192
Total Current Assets		 1,042 1,588 2,519 1,563 772 403 118
Cash & Equivalents		 223 242 849 348 437 109 48
Restricted Cash		 89 13 13 8.59 7.99 6.18 11
Short-Term Investments		 682 1,281 1,553 360 300 274 51
Prepaid Expenses		 48 53 104 73 28 13 8.58
Plant, Property, & Equipment, net		 63 96 106 43 18 16 12
Total Noncurrent Assets		 293 235 177 349 128 93 62
Long-Term Investments		 190 105 24 201 0.00 24 0.00
Goodwill		 17 17 17 17 17 17 17
Intangible Assets		 8.12 23 33 33 34 36 37
Other Noncurrent Operating Assets		 72 84 97 90 71 8.55 6.67
Other Noncurrent Nonoperating Assets		 6.36 6.45 6.66 7.01 6.92 7.30 1.00
Total Liabilities & Shareholders' Equity		 1,399 1,919 2,802 1,954 919 512 192
Total Liabilities		 248 329 724 522 202 88 62
Total Current Liabilities		 120 175 511 341 99 59 40
Short-Term Debt		 16 0.00 - 0.00 11 8.20 0.00
Accounts Payable		 5.08 6.33 6.42 6.52 5.08 5.88 6.47
Accrued Expenses		 86 104 489 237 77 26 15
Current Deferred Revenue		 13 65 16 98 6.45 6.18 8.76
Total Noncurrent Liabilities		 129 153 213 181 103 29 22
Other Noncurrent Operating Liabilities		 129 153 160 159 96 13 11
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,150 1,590 2,078 1,432 717 424 -179
Total Preferred & Common Equity		 1,150 1,590 2,078 1,432 717 424 -179
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,150 1,590 2,078 1,432 717 424 -179
Common Stock		 1,912 1,829 1,710 1,572 1,385 793 15
Retained Earnings		 -760 -238 377 -139 -667 -369 -194
Accumulated Other Comprehensive Income / (Loss)		 -1.72 -0.82 -9.12 -1.10 -1.28 -0.60 -0.01

Quarterly Balance Sheets for Vir Biotechnology

This table presents Vir Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 1,308 1,498 1,670 1,794 2,045 2,244 2,666 2,696
Total Current Assets		 932 1,047 1,206 1,213 1,769 1,946 2,359 2,414
Cash & Equivalents		 274 168 297 161 452 667 825 964
Restricted Cash		 88 90 14 13 13 13 11 13
Short-Term Investments		 528 746 854 989 1,244 1,180 1,425 1,360
Prepaid Expenses		 42 43 41 50 59 86 98 54
Plant, Property, & Equipment, net		 62 65 66 92 99 104 104 100
Total Noncurrent Assets		 314 386 398 488 176 193 204 182
Long-Term Investments		 218 271 280 360 40 52 49 34
Goodwill		 17 17 17 17 17 17 17 17
Intangible Assets		 8.07 19 19 22 25 26 33 33
Other Noncurrent Operating Assets		 64 72 76 83 87 92 98 91
Other Noncurrent Nonoperating Assets		 6.27 6.38 6.37 6.43 7.06 6.74 6.74 7.28
Total Liabilities & Shareholders' Equity		 1,308 1,498 1,670 1,794 2,045 2,244 2,666 2,696
Total Liabilities		 264 258 236 247 370 434 695 546
Total Current Liabilities		 137 117 96 94 165 226 485 308
Short-Term Debt		 18 - - - - - - -
Accounts Payable		 3.73 7.31 4.39 7.11 3.63 12 12 2.72
Accrued Expenses		 104 95 75 72 146 198 456 283
Current Deferred Revenue		 12 15 17 15 15 16 17 23
Total Noncurrent Liabilities		 127 140 139 153 205 208 210 238
Other Noncurrent Operating Liabilities		 127 140 139 151 152 155 153 165
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,044 1,241 1,434 1,547 1,675 1,810 1,971 2,150
Total Preferred & Common Equity		 1,044 1,241 1,434 1,547 1,675 1,810 1,971 2,150
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,044 1,241 1,434 1,547 1,675 1,810 1,971 2,150
Common Stock		 1,927 1,895 1,878 1,853 1,799 1,772 1,738 1,683
Retained Earnings		 -881 -655 -441 -303 -122 42 236 479
Accumulated Other Comprehensive Income / (Loss)		 -1.98 1.13 -2.88 -2.40 -1.90 -2.90 -3.22 -12

Annual Metrics And Ratios for Vir Biotechnology

This table displays calculated financial ratios and metrics derived from Vir Biotechnology's official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Growth Metrics		 - - - - - - - -
Revenue Growth		 -13.90% -94.67% 47.51% 1,334.39% 843.86% -24.16% 293.94% 0.00%
EBITDA Growth		 18.38% -197.29% 30.47% 288.46% -64.78% -53.42% -43.83% 0.00%
EBIT Growth		 16.82% -198.48% 32.19% 282.24% -64.69% -53.94% -46.05% 0.00%
NOPAT Growth		 14.20% -184.08% 40.84% 294.58% -66.86% -49.95% -45.64% 0.00%
Net Income Growth		 15.14% -219.25% -2.41% 276.98% -70.98% -50.74% -65.90% 0.00%
EPS Growth		 16.56% -219.84% -3.28% 257.77% 56.42% 61.90% 53.41% 0.00%
Operating Cash Flow Growth		 42.69% -146.82% 3,595.04% 75.08% -47.29% -37.77% -41.75% 0.00%
Free Cash Flow Firm Growth		 43.80% -154.66% 1,241.11% 26.71% -50.45% -10.48% 0.00% 0.00%
Invested Capital Growth		 56.85% 84.44% -172.49% 2,183.45% -322.41% -47.37% 0.00% 0.00%
Revenue Q/Q Growth		 -5.61% -27.46% -32.08% 285.18% 1.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 3.67% 5.10% -49.91% 674.37% -15.57% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 3.67% 3.55% -49.56% 639.22% -15.28% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 3.59% 1.65% -53.46% 322.77% -17.69% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 2.13% -2.39% -54.86% 616.60% -16.31% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 2.30% -2.68% -55.31% 540.00% -162.44% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 4.35% -22.50% 1.68% 65.35% -29.21% -7.80% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 4.91% -20.18% -1.61% 29.04% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 40.16% 29.72% -46.37% 6,607.20% -439.99% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - -
Gross Margin		 98.86% 96.79% 90.94% 93.99% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -774.82% -817.40% 44.81% 50.66% -385.58% -2,208.65% -1,091.83% -2,990.47%
Operating Margin		 -791.27% -794.04% 51.56% 38.41% -388.88% -2,199.72% -1,112.60% -3,009.49%
EBIT Margin		 -801.72% -829.87% 44.94% 50.15% -394.73% -2,262.27% -1,114.59% -3,006.43%
Profit (Net Income) Margin		 -703.40% -713.76% 31.92% 48.25% -391.09% -2,158.98% -1,086.28% -2,579.47%
Tax Burden Percent		 99.78% 97.92% 68.39% 96.14% 100.02% 100.09% 99.59% 86.48%
Interest Burden Percent		 87.93% 87.84% 103.87% 100.08% 99.06% 95.35% 97.86% 99.22%
Effective Tax Rate		 0.00% 0.00% 31.61% 3.86% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 817.53% 167.71% 0.00% -785.73% -799.77% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 820.73% 152.82% 0.00% -766.54% -739.69% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% -788.14% -118.51% 0.00% 722.66% 621.43% 0.00%
Return on Equity (ROE)		 -38.09% -33.54% 29.39% 49.20% -52.36% -63.07% -178.34% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -24.97% 0.00% -723.66% -999.77% 0.00%
Operating Return on Assets (OROA)		 -35.86% -30.30% 30.54% 38.24% -42.14% -52.02% -62.06% 0.00%
Return on Assets (ROA)		 -31.46% -26.06% 21.69% 36.80% -41.75% -49.65% -60.48% 0.00%
Return on Common Equity (ROCE)		 -38.09% -33.54% 29.39% 49.20% -52.36% -27.87% 245.88% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -45.37% -38.68% 24.82% 36.92% -41.66% -41.20% 64.68% 0.00%
Net Operating Profit after Tax (NOPAT)		 -411 -479 570 405 -208 -125 -83 -57
NOPAT Margin		 -553.89% -555.83% 35.26% 36.93% -272.22% -1,539.80% -778.82% -2,106.64%
Net Nonoperating Expense Percent (NNEP)		 -7.86% -6.65% -3.20% 14.89% -15.73% -19.19% -60.08% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -35.24% -30.12% 27.42% - - - - -
Cost of Revenue to Revenue		 1.14% 3.21% 9.06% 6.01% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 160.41% 202.41% 10.01% 14.68% 92.89% 464.69% 273.07% 801.07%
R&D to Revenue		 682.57% 672.69% 29.38% 40.90% 395.99% 1,835.03% 939.53% 2,308.42%
Operating Expenses to Revenue		 890.14% 890.83% 39.39% 55.58% 488.88% 2,299.72% 1,212.60% 3,109.49%
Earnings before Interest and Taxes (EBIT)		 -595 -715 726 549 -301 -183 -119 -81
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -575 -704 724 555 -294 -179 -116 -81
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.88 0.85 1.62 3.83 4.76 3.25 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.90 0.87 1.66 3.97 5.12 3.71 0.00 0.00
Price to Revenue (P/Rev)		 13.62 15.70 2.09 5.00 44.67 170.46 13.39 52.75
Price to Earnings (P/E)		 0.00 0.00 6.53 10.37 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 15.31% 9.65% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 9.00 0.00 89.03 16.50 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.58 4.16 35.06 120.32 32.13 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 1.29 8.22 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 1.28 8.30 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 1.63 11.28 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.56 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.64 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.01 0.00 0.00 0.00 0.01 0.02 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.12 -0.96 -0.78 -1.01 -0.94 -0.84 0.00
Leverage Ratio		 1.21 1.29 1.36 1.34 1.25 1.27 1.47 0.00
Compound Leverage Factor		 1.06 1.13 1.41 1.34 1.24 1.21 1.44 0.00
Debt to Total Capital		 1.38% 0.00% 0.00% 0.00% 1.46% 1.90% 0.00% 0.00%
Short-Term Debt to Total Capital		 1.38% 0.00% 0.00% 0.00% 1.46% 1.90% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 237.87% 0.00%
Common Equity to Total Capital		 98.62% 100.00% 100.00% 100.00% 98.54% 98.10% -137.87% 0.00%
Debt to EBITDA		 -0.03 0.00 0.00 0.00 -0.04 -0.05 0.00 0.00
Net Debt to EBITDA		 2.03 0.00 0.00 0.00 2.49 2.27 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.04 0.00 0.00 0.00 -0.05 -0.07 0.00 0.00
Net Debt to NOPAT		 2.84 0.00 0.00 0.00 3.53 3.26 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 1.12 1.99 5.27 8.43 9.00 8.02 -1.53 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 55.81% 237.87% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 8.71 9.05 4.93 4.58 7.80 6.81 2.95 0.00
Quick Ratio		 7.57 8.68 4.70 4.34 7.44 6.48 2.47 0.00
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -444 -789 1,444 -127 -173 -115 -104 0.00
Operating Cash Flow to CapEx		 -11,360.45% -3,610.00% 2,445.74% -218.13% -2,915.57% -1,450.02% -949.51% -2,420.90%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.04 0.04 0.68 0.76 0.11 0.02 0.06 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.93 0.85 21.77 36.05 4.46 0.57 0.87 0.00
Accounts Payable Turnover		 0.15 0.43 22.61 11.36 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 2,465.37 841.94 16.14 32.14 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -2,465.37 -841.94 -16.14 -32.14 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 -25 -57 -367 507 -24 11 21 0.00
Invested Capital Turnover		 -1.81 -0.41 23.19 4.54 -11.41 0.51 1.03 0.00
Increase / (Decrease) in Invested Capital		 32 310 -874 531 -35 -9.84 21 0.00
Enterprise Value (EV)		 -158 -288 931 4,562 2,677 974 343 0.00
Market Capitalization		 1,011 1,353 3,369 5,480 3,411 1,379 143 143
Book Value per Share		 $8.35 $11.82 $15.61 $10.94 $5.63 $3.87 ($23.37) $0.00
Tangible Book Value per Share		 $8.17 $11.53 $15.24 $10.56 $5.23 $3.39 ($30.40) $0.00
Total Capital		 1,166 1,590 2,078 1,432 727 432 130 0.00
Total Debt		 16 0.00 0.00 0.00 11 8.20 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,169 -1,641 -2,439 -918 -734 -406 -109 0.00
Capital Expenditures (CapEx)		 3.93 22 68 22 6.55 8.94 9.91 2.74
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -56 -123 -407 505 -61 -38 -31 0.00
Debt-free Net Working Capital (DFNWC)		 939 1,413 2,008 1,222 684 352 78 0.00
Net Working Capital (NWC)		 923 1,413 2,008 1,222 673 344 78 0.00
Net Nonoperating Expense (NNE)		 111 136 54 -124 91 50 33 13
Net Nonoperating Obligations (NNO)		 -1,175 -1,647 -2,445 -925 -741 -413 -109 0.00
Total Depreciation and Amortization (D&A)		 20 11 -2.16 5.57 6.99 4.34 2.43 0.43
Debt-free, Cash-free Net Working Capital to Revenue		 -75.30% -142.56% -25.17% 46.09% -79.81% -465.06% -293.67% 0.00%
Debt-free Net Working Capital to Revenue		 1,265.22% 1,639.38% 124.28% 111.52% 895.53% 4,350.38% 729.99% 0.00%
Net Working Capital to Revenue		 1,243.58% 1,639.38% 124.28% 111.52% 881.65% 4,249.03% 729.99% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.83) ($4.59) $3.89 $4.07 ($2.51) ($5.76) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 136.25M 134.13M 132.61M 129.88M 127.84M 109.80M 0.00 0.00
Adjusted Diluted Earnings per Share		 ($3.83) ($4.59) $3.83 $3.96 ($2.51) ($5.76) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 136.25M 134.13M 134.81M 133.44M 127.84M 109.80M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($2.51) ($5.76) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 137.14M 135.03M 133.53M 132.30M 119.16M 30.35M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -387 -470 570 405 -208 -125 -83 -57
Normalized NOPAT Margin		 -520.88% -544.82% 35.26% 36.93% -272.22% -1,539.80% -778.82% -2,106.64%
Pre Tax Income Margin		 -704.95% -728.93% 46.68% 50.19% -391.02% -2,157.08% -1,090.78% -2,982.87%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Vir Biotechnology

This table displays calculated financial ratios and metrics derived from Vir Biotechnology's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -94.62% -26.29% -9.81% -19.02% -10.45% -66.03% -99.30% 109.35% -94.89% -93.92% 261.49%
EBITDA Growth		 -54.89% 16.13% -25.41% 30.63% 51.54% 21.80% -187.74% 6.32% -118.20% -131.67% 85.49%
EBIT Growth		 -54.42% 16.02% -22.54% 28.06% 47.55% 15.68% -190.48% 6.48% -117.85% -130.75% 88.17%
NOPAT Growth		 -74.26% 15.73% -23.87% 26.28% 44.14% 7.63% -183.27% 4.46% -117.60% -119.15% 394.94%
Net Income Growth		 -85.31% 9.82% -30.78% 28.95% 53.69% -14.14% -193.21% -154.63% -127.18% -119.34% 58.76%
EPS Growth		 -83.33% 10.47% -27.87% 29.66% 54.72% -16.22% -193.85% -150.00% -127.53% -118.50% 58.54%
Operating Cash Flow Growth		 28.59% 18.80% -10.04% 80.00% 13.03% -407.26% -232.17% -140.54% -122.87% 356.48% 211.42%
Free Cash Flow Firm Growth		 93.65% 71.90% 32.73% 49.78% -271.00% -153.01% -175.06% -618.49% -50.55% 3,924.14% 901.25%
Invested Capital Growth		 -392.21% 56.85% 49.32% 83.84% 105.23% 84.44% 67.59% 69.82% 0.00% -172.49% -3,122.79%
Revenue Q/Q Growth		 -75.50% 419.92% -22.60% -94.55% 235.83% 536.11% -30.50% -93.97% 27.42% -86.81% 1,021.90%
EBITDA Q/Q Growth		 -10.99% 50.06% -50.04% -86.24% 39.90% 25.32% 17.01% -30.12% 3.03% -183.80% 188.60%
EBIT Q/Q Growth		 -12.13% 48.57% -45.57% -83.97% 39.02% 24.96% 14.54% -34.13% 1.98% -180.52% 188.33%
NOPAT Q/Q Growth		 -19.12% 49.35% -45.81% -98.09% 42.39% 25.55% 13.22% -50.09% 4.74% -167.11% 199.57%
Net Income Q/Q Growth		 -15.66% 51.06% -54.44% -111.99% 43.71% 29.03% 16.10% -38.18% -38.73% -157.96% 329.19%
EPS Q/Q Growth		 -14.29% 50.64% -52.94% -112.50% 44.19% 29.51% 15.86% -36.79% -43.24% -156.92% 324.14%
Operating Cash Flow Q/Q Growth		 10.86% 48.89% -120.28% 28.84% -1.36% 30.74% 59.97% -209.46% -458.09% -70.21% -87.72%
Free Cash Flow Firm Q/Q Growth		 76.71% 43.32% 0.40% 51.74% -3.15% -35.68% 25.64% -264.33% -68.02% 92.10% 413.66%
Invested Capital Q/Q Growth		 -114.49% 40.16% -132.91% -197.75% 131.67% 29.72% 25.71% 68.37% 5.77% -46.37% 30.82%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 94.47% 97.90% 98.31% 99.90% 95.25% 98.56% 99.42% 96.97% 87.86% 94.06%
EBITDA Margin		 -4,164.94% -919.46% -9,572.14% -4,937.85% -144.61% -808.14% -6,883.74% -5,764.87% -267.20% -351.11% 55.27%
Operating Margin		 -4,602.47% -946.74% -9,718.66% -5,158.70% -142.05% -828.12% -7,075.86% -5,667.26% -227.73% -304.60% 52.05%
EBIT Margin		 -4,394.36% -960.30% -9,708.70% -5,162.15% -153.05% -842.87% -7,145.02% -5,810.88% -261.28% -339.63% 55.64%
Profit (Net Income) Margin		 -3,989.61% -845.23% -8,979.71% -4,500.10% -115.79% -690.85% -6,192.23% -5,129.71% -223.89% -205.63% 46.81%
Tax Burden Percent		 100.01% 99.92% 100.08% 98.92% 100.42% 96.04% 98.07% 98.56% 98.44% 67.00% 80.52%
Interest Burden Percent		 90.78% 88.09% 92.41% 88.13% 75.33% 85.34% 88.37% 89.57% 87.05% 90.36% 104.48%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 19.48%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,943.76% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,943.98% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,747.66% 0.00%
Return on Equity (ROE)		 -44.59% -38.09% -36.58% -29.78% -30.67% -33.54% -31.41% -13.93% -7.29% -196.10% 75.52%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -4,412.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -59.11% -42.95% -430.84% -208.09% -5.46% -30.77% -358.10% -1,172.77% -43.74% -230.75% 67.78%
Return on Assets (ROA)		 -53.67% -37.81% -398.49% -181.40% -4.13% -25.22% -310.35% -1,035.30% -37.48% -139.71% 57.02%
Return on Common Equity (ROCE)		 -44.59% -38.09% -36.58% -29.78% -30.67% -33.54% -31.41% -13.93% -7.29% -196.10% 75.52%
Return on Equity Simple (ROE_SIMPLE)		 -55.34% 0.00% -42.99% -33.69% -34.86% 0.00% -35.86% -14.47% -7.29% 0.00% 53.15%
Net Operating Profit after Tax (NOPAT)		 -98 -82 -162 -111 -56 -97 -131 -151 -100 -105 157
NOPAT Margin		 -3,221.73% -662.72% -6,803.06% -3,611.09% -99.43% -579.68% -4,953.10% -3,967.08% -159.41% -213.22% 41.91%
Net Nonoperating Expense Percent (NNEP)		 -1.77% -1.60% -3.41% -1.62% -0.48% -0.91% -1.57% -2.09% -3.50% 0.22% 1.12%
Return On Investment Capital (ROIC_SIMPLE)		 -9.20% -7.03% - - - -6.12% - - - -5.07% -
Cost of Revenue to Revenue		 0.00% 5.53% 2.10% 1.69% 0.10% 4.75% 1.44% 0.58% 3.03% 12.14% 5.94%
SG&A Expenses to Revenue		 789.71% 216.17% 1,081.68% 984.23% 64.34% 245.54% 1,551.08% 1,198.63% 74.30% 78.41% 11.53%
R&D to Revenue		 3,913.09% 857.31% 8,200.76% 3,418.31% 177.60% 649.11% 5,495.57% 4,426.73% 250.40% 314.05% 30.48%
Operating Expenses to Revenue		 4,702.47% 1,041.22% 9,816.55% 5,257.01% 241.94% 923.36% 7,174.42% 5,766.68% 324.70% 392.46% 42.01%
Earnings before Interest and Taxes (EBIT)		 -133 -119 -231 -159 -86 -141 -189 -221 -164 -168 208
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -126 -114 -228 -152 -82 -136 -182 -219 -168 -173 207
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.85 0.88 0.82 0.84 0.88 0.85 0.75 1.82 1.58 1.62 1.19
Price to Tangible Book Value (P/TBV)		 0.87 0.90 0.85 0.87 0.90 0.87 0.77 1.86 1.62 1.66 1.22
Price to Revenue (P/Rev)		 42.60 13.62 13.02 15.35 17.12 15.70 10.59 6.70 6.96 2.09 1.07
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.53 2.24
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 15.31% 44.68%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.80 1.79 0.58 0.08
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.29 0.13
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.28 0.13
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.63 0.15
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.81 0.56 0.11
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.68 0.64 0.13
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.02 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -1.03 -1.04 -1.04 -1.09 -1.12 -1.09 -1.13 -1.18 -0.96 -1.09
Leverage Ratio		 1.20 1.21 1.22 1.21 1.27 1.29 1.24 1.29 1.35 1.36 1.29
Compound Leverage Factor		 1.09 1.07 1.12 1.06 0.96 1.10 1.10 1.16 1.18 1.22 1.35
Debt to Total Capital		 1.65% 1.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 1.65% 1.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 98.35% 98.62% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.03 -0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 1.76 2.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.04 -0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 2.41 2.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 1.49 2.25 2.06 3.24 3.71 2.98 2.65 5.39 3.61 4.22 5.13
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.79 8.71 8.94 12.51 12.90 9.05 10.72 8.63 4.86 4.93 7.83
Quick Ratio		 5.84 7.57 7.81 11.94 12.22 8.68 10.28 8.19 4.64 4.70 7.54
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -27 -115 -202 -203 -420 -407 -300 -404 246 769 400
Operating Cash Flow to CapEx		 -5,794.96% 0.00% -7,293.92% -27,124.39% -8,169.53% -7,031.07% -4,195.72% -4,115.97% -1,831.69% 278.87% 621.13%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.04 0.04 0.04 0.04 0.04 0.05 0.20 0.17 0.68 1.22
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.27 0.93 0.96 0.93 0.81 0.85 1.19 5.19 4.30 21.77 37.52
Accounts Payable Turnover		 0.15 0.15 0.18 0.11 0.10 0.43 2.51 2.63 4.78 22.61 56.78
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 2,516.69 2,465.37 2,080.39 3,228.15 3,833.69 841.94 145.51 138.97 76.35 16.14 6.43
Cash Conversion Cycle (CCC)		 -2,516.69 -2,465.37 -2,080.39 -3,228.15 -3,833.69 -841.94 -145.51 -138.97 -76.35 -16.14 -6.43
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -53 -25 -41 -18 18 -57 -81 -109 -346 -367 -251
Invested Capital Turnover		 -1.20 -1.81 -1.28 -1.24 -0.49 -0.41 -0.72 -2.08 -2.58 23.19 -18.39
Increase / (Decrease) in Invested Capital		 -71 32 40 92 364 310 170 253 -346 -874 -243
Enterprise Value (EV)		 -202 -158 -252 -234 -160 -288 -491 1,373 797 931 187
Market Capitalization		 889 1,011 1,023 1,211 1,363 1,353 1,258 3,286 3,107 3,369 2,557
Book Value per Share		 $7.61 $8.35 $9.08 $10.54 $11.44 $11.82 $12.48 $13.51 $14.76 $15.61 $16.21
Tangible Book Value per Share		 $7.43 $8.17 $8.82 $10.27 $11.15 $11.53 $12.16 $13.19 $14.39 $15.24 $15.83
Total Capital		 1,061 1,166 1,241 1,434 1,547 1,590 1,675 1,810 1,971 2,078 2,150
Total Debt		 18 16 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,090 -1,169 -1,276 -1,445 -1,523 -1,641 -1,749 -1,913 -2,310 -2,439 -2,371
Capital Expenditures (CapEx)		 1.35 -0.05 2.35 0.29 1.34 1.54 3.71 9.46 6.87 13 19
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -77 -56 -74 -56 -44 -123 -106 -140 -388 -407 -231
Debt-free Net Working Capital (DFNWC)		 812 939 930 1,109 1,119 1,413 1,604 1,721 1,873 2,008 2,105
Net Working Capital (NWC)		 795 923 930 1,109 1,119 1,413 1,604 1,721 1,873 2,008 2,105
Net Nonoperating Expense (NNE)		 23 23 52 27 9.22 19 33 44 41 -3.75 -18
Net Nonoperating Obligations (NNO)		 -1,097 -1,175 -1,282 -1,451 -1,529 -1,647 -1,756 -1,920 -2,317 -2,445 -2,401
Total Depreciation and Amortization (D&A)		 6.96 5.05 3.25 6.90 4.76 5.83 6.90 1.75 -3.73 -5.68 -1.37
Debt-free, Cash-free Net Working Capital to Revenue		 -370.99% -75.30% -94.22% -70.59% -55.36% -142.56% -88.90% -28.51% -86.87% -25.17% -9.72%
Debt-free Net Working Capital to Revenue		 3,894.45% 1,265.22% 1,182.93% 1,406.40% 1,405.83% 1,639.38% 1,350.24% 350.65% 419.76% 124.28% 88.49%
Net Working Capital to Revenue		 3,810.56% 1,243.58% 1,182.93% 1,406.40% 1,405.83% 1,639.38% 1,350.24% 350.65% 419.76% 124.28% 88.49%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.88) ($0.77) ($1.56) ($1.02) ($0.48) ($0.86) ($1.22) ($1.45) ($1.06) ($0.78) $1.32
Adjusted Weighted Average Basic Shares Outstanding		 137.47M 136.25M 136.65M 136.23M 135.28M 134.13M 134.29M 134.06M 133.55M 132.61M 132.73M
Adjusted Diluted Earnings per Share		 ($0.88) ($0.77) ($1.56) ($1.02) ($0.48) ($0.86) ($1.22) ($1.45) ($1.06) ($0.74) $1.30
Adjusted Weighted Average Diluted Shares Outstanding		 137.47M 136.25M 136.65M 136.23M 135.28M 134.13M 134.29M 134.06M 133.55M 134.81M 134.96M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 138.24M 137.14M 137.72M 136.64M 136.06M 135.03M 134.52M 134.25M 133.98M 133.53M 133.12M
Normalized Net Operating Profit after Tax (NOPAT)		 -98 -82 -153 -93 -56 -97 -128 -147 -100 -105 157
Normalized NOPAT Margin		 -3,221.96% -662.72% -6,429.18% -3,012.96% -99.43% -579.68% -4,863.66% -3,868.16% -159.41% -213.22% 41.91%
Pre Tax Income Margin		 -3,989.08% -845.93% -8,972.27% -4,549.27% -115.30% -719.35% -6,313.98% -5,204.71% -227.44% -306.90% 58.13%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.02% -0.04% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.02% -0.04% 0.00% 0.00% 0.00%

Frequently Asked Questions About Vir Biotechnology's Financials

When does Vir Biotechnology's fiscal year end?

According to the most recent income statement we have on file, Vir Biotechnology's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Vir Biotechnology's net income changed over the last 7 years?

Vir Biotechnology's net income appears to be on an upward trend, with a most recent value of -$521.96 million in 2024, rising from -$69.85 million in 2017. The previous period was -$615.12 million in 2023. View Vir Biotechnology's forecast to see where analysts expect Vir Biotechnology to go next.

What is Vir Biotechnology's operating income?
Vir Biotechnology's total operating income in 2024 was -$587.17 million, based on the following breakdown:
  • Total Gross Profit: $73.36 million
  • Total Operating Expenses: $660.53 million
How has Vir Biotechnology revenue changed over the last 7 years?

Over the last 7 years, Vir Biotechnology's total revenue changed from $2.71 million in 2017 to $74.21 million in 2024, a change of 2,640.2%.

How much debt does Vir Biotechnology have?

Vir Biotechnology's total liabilities were at $248.43 million at the end of 2024, a 24.4% decrease from 2023, and a 303.1% increase since 2018.

How much cash does Vir Biotechnology have?

In the past 6 years, Vir Biotechnology's cash and equivalents has ranged from $47.60 million in 2018 to $848.63 million in 2022, and is currently $222.95 million as of their latest financial filing in 2024.

How has Vir Biotechnology's book value per share changed over the last 7 years?

Over the last 7 years, Vir Biotechnology's book value per share changed from 0.00 in 2017 to 8.35 in 2024, a change of 835.3%.


Related Companies

This page (NASDAQ:VIR) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored